Skip to main navigation Skip to search Skip to main content

Impact of Toxicity on Survival for Older Adult Patients after CD34 + Selected Allogeneic Hematopoietic Stem Cell Transplantation

  • Gunjan L. Shah
  • , Michael Scordo
  • , Satyajit Kosuri
  • , Diego Adrianzen Herrera
  • , Christina Cho
  • , Sean M. Devlin
  • , Taylor Borrill
  • , Dean C. Carlow
  • , Scott T. Avecilla
  • , Richard C. Meagher
  • , Richard J. O'Reilly
  • , Ann A. Jakubowski
  • , Esperanza B. Papadopoulos
  • , Guenther Koehne
  • , Boglarka Gyurkocza
  • , Hugo Castro-Malaspina
  • , Brian C. Shaffer
  • , Miguel Angel Perales
  • , Sergio A. Giralt
  • , Roni Tamari
  • Memorial Sloan-Kettering Cancer Center
  • Cornell University
  • The University of Chicago
  • Albert Einstein College of Medicine

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Ex vivo CD34 + selection before allogeneic hematopoietic stem cell transplantation (allo-HCT) reduces graft-versus-host disease without increasing relapse but usually requires myeloablative conditioning. We aimed to identify toxicity patterns in older patients and the association with overall survival (OS) and nonrelapse mortality (NRM). We conducted a retrospective analysis of 200 patients who underwent CD34 + selection allo-HCT using the ClinicMACS® system between 2006 and 2012. All grade 3 to 5 toxicities by CTCAE v4.0 were collected. Eighty patients aged ≥ 60 years with a median age of 64 (range, 60 to 73) were compared with 120 patients aged < 60 years. Median follow-up in survivors was 48.2 months. OS and NRM were similar between ages ≥ 60 and <60, with 1-year OS 70% versus 78% (P =.07) and 1-year NRM 23% versus 13% (P =.38), respectively. In patients aged ≥ 60 the most common toxicities by day 100 were metabolic, with a cumulative incidence of 88% (95% CI, 78% to 93%), infectious 84% (95% CI, 73% to 90%), hematologic 80% (95% CI, 69% to 87%), oral/gastrointestinal (GI) 48% (95% CI, 36% to 58%), cardiovascular (CV) 35% (95% CI, 25% to 46%), and hepatic 25% (95% CI, 16% to 35%). Patients aged ≥ 60 had a higher risk of neurologic (HR, 2.63 [95% CI, 1.45 to 4.78]; P =.001) and CV (HR, 1.65 [95% CI, 1.04 to 2.63]; P =.03) toxicities but a lower risk of oral/GI (HR,.58 [95% CI,.41 to.83]; P =.003) compared with those aged < 60. CV, hepatic, neurologic, pulmonary, and renal toxicities remained independent risk factors for the risk of death and NRM in separate multivariate models adjusting for age and hematopoietic cell transplantation–specific comorbidity index. Overall, the toxicity of a more intense regimen is potentially balanced by the absence of toxicity related to methotrexate and calcineurin inhibitors in older patients. Prospective study of toxicities after allo-HCT in older patients is essential.

Original languageEnglish
Pages (from-to)142-149
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume24
Issue number1
DOIs
StatePublished - Jan 2018

Keywords

  • Allogeneic hematopoietic cell
  • Ex vivo CD34 selection
  • Geriatric oncology
  • GVHD
  • T cell depletion
  • Toxicities
  • Transplant

Fingerprint

Dive into the research topics of 'Impact of Toxicity on Survival for Older Adult Patients after CD34 + Selected Allogeneic Hematopoietic Stem Cell Transplantation'. Together they form a unique fingerprint.

Cite this